Media stories about Genetic Technologies (NASDAQ:GENE) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genetic Technologies earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0894991360372 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- U.S. scientists edit out disease from human embryos for first time (nydailynews.com)
- Thinking About a BigY Test at Family Tree DNA? (thegeneticgenealogist.com)
- Biotechnology: the US-China dispute over genetic data (ft.com)
- Novel Genetic Test Could Help Combat the Opioid Epidemic by Identifying Patients at Risk of Addiction (bizjournals.com)
- Gene Editing Market Production, Share, Demand, Applications and Opportunities Market Research Report 2024 (medgadget.com)
Shares of Genetic Technologies (NASDAQ GENE) traded down 2.33% during mid-day trading on Thursday, reaching $0.84. 40,769 shares of the company’s stock were exchanged. Genetic Technologies has a 52 week low of $0.75 and a 52 week high of $2.89. The stock has a 50 day moving average price of $0.86 and a 200 day moving average price of $1.06. The stock’s market cap is $13.64 million.
ILLEGAL ACTIVITY NOTICE: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/08/03/genetic-technologies-nasdaqgene-earns-media-impact-rating-of-0-18.html.
About Genetic Technologies
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.
Receive News & Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related companies with MarketBeat.com's FREE daily email newsletter.